Elite Journal of Haematology. Volume 2 issue 3(2024), Pp. 1-9
https://epjournals.com/journals/EJH

Unraveling the Puzzle: COVID-19's Influence on Hemostasis Mechanisms

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]School of Nursing Science, Kampala International University, Uganda

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda. emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug 0000-0002-4538-0161

Abstract

In the wake of the global COVID-19 pandemic, a growing body of evidence underscores the intricate relationship between the virus and hemostasis mechanisms, unraveling a complex puzzle that demands attention from both the medical and scientific communities. This review article delves into the multifaceted impact of COVID-19 on hemostasis, shedding light on the virus's influence on coagulation pathways, platelet function, and vascular dynamics. Keywords such as thrombosis, fibrinolysis, and endothelial dysfunction take center stage as we explore the intricate dance between the SARS-CoV-2 virus and the body's clotting mechanisms. With a focus on recent research findings, clinical observations, and potential therapeutic interventions, this review aims to provide a comprehensive overview of the evolving understanding of COVID-19's effects on hemostasis. As we navigate this challenging intersection of infectious disease and coagulation biology, unlocking the mysteries of COVID-19's influence on hemostasis is crucial for informing clinical management strategies and advancing our broader understanding of viral pathogenesis.

Keywords*: COVID-19, SARS-CoV-2, hemostasis, coagulation, thrombosis, fibrinolysis, endothelial dysfunction, inflammatory response*

Introduction

The emergence of the COVID-19 pandemic has not only presented an unprecedented health crisis but has also brought to the forefront the intricate interplay between the SARS-CoV-2 virus and the host's hemostasis mechanisms. This review article aims to unravel the complex puzzle surrounding

Citation: Obeagu EI, Obeagu GU. Unraveling the Puzzle: COVID-19's Influence on Hemostasis Mechanisms. *Elite Journal of Haematology, 2024; 2(3):* 1-9

COVID-19's influence on hemostasis, exploring the multifaceted connections that exist between the viral infection and the intricate web of coagulation, platelet function, and vascular dynamics. As healthcare professionals and scientists grapple with the diverse clinical manifestations of COVID-19, understanding the impact on hemostasis becomes imperative for informing therapeutic strategies and improving patient outcomes. The phenomenon of COVID-19-associated coagulopathy has become a focal point of investigation, with growing evidence suggesting an increased risk of thrombotic events in infected individuals. By dissecting these intricacies, we aim to contribute to the evolving knowledge base surrounding COVID-19 pathology, laying the groundwork for more targeted and effective therapeutic interventions.[1-17]

Furthermore, our exploration extends to the impact of COVID-19 on platelet function, considering alterations in platelet activation, aggregation, and the potential role of platelets in the inflammatory response. Understanding these facets is crucial for comprehending the broader implications of the virus on hemostasis and vascular health. Through a synthesis of recent research findings and clinical observations, this review endeavors to provide a holistic perspective on the dynamic interactions between COVID-19 and the intricate landscape of hemostasis. In addition to coagulation and platelet dynamics, attention is directed towards the profound influence of COVID-19 on endothelial function. The virus's ability to induce endothelial dysfunction is a key aspect that has been implicated in the development of severe vascular complications. This review explores the underlying mechanisms through which the virus interacts with endothelial cells, disrupting vascular homeostasis and contributing to the overall pathophysiology of COVID-19.

COVID-19 and Coagulation

The relationship between COVID-19 and coagulation has emerged as a critical aspect of understanding the complexities of this viral infection. Since the early stages of the pandemic, it became evident that COVID-19 patients were at an increased risk of thrombotic events, ranging from deep vein thrombosis to pulmonary embolism. One of the hallmark features of severe COVID-19 cases is the development of a prothrombotic state, characterized by elevated levels of clotting factors and fibrinogen. Studies have shown that the virus can directly impact the endothelium, leading to endothelial dysfunction and activation. This endothelial involvement plays a pivotal role in the dysregulation of anticoagulant pathways and the promotion of a hypercoagulable state. Understanding these molecular and cellular interactions is crucial for tailoring therapeutic interventions to mitigate the risk of thrombotic complications in COVID-19 patients. The spectrum of coagulation abnormalities in COVID-19 extends beyond the traditional pathways, encompassing platelet dysfunction as well. Research indicates that the virus can induce platelet activation and aggregation, contributing to the formation of microthrombi and exacerbating the coagulopathic profile. This nuanced understanding of platelet dynamics in COVID-19 adds another layer to the intricate relationship between the virus and hemostasis.[18-31]

Citation: Obeagu EI, Obeagu GU. Unraveling the Puzzle: COVID-19's Influence on Hemostasis Mechanisms. *Elite Journal of Haematology, 2024; 2(3):* 1-9

Moreover, the role of inflammation in the coagulation cascade during COVID-19 cannot be understated. The virus triggers an intense inflammatory response, leading to a cytokine storm that further amplifies coagulation pathways. The interplay between inflammation and coagulation creates a vicious cycle, potentially fueling the severity of the disease and complicating clinical management. As the medical community grapples with the challenges posed by COVID-19, unraveling the mysteries of its impact on coagulation is essential for informing therapeutic strategies and improving patient outcomes. From anticoagulation protocols to novel treatments targeting specific aspects of the coagulation cascade, ongoing research endeavors aim to translate scientific insights into practical clinical applications. Ultimately, a comprehensive understanding of COVID-19 and coagulation is vital not only for managing the immediate health implications but also for addressing the potential long-term consequences of this viral infection on vascular health.[32-36]

Thrombosis and Fibrinolysis

Thrombosis and fibrinolysis play pivotal roles in the intricate balance of hemostasis, maintaining vascular integrity and preventing excessive bleeding. However, in the context of diseases such as COVID-19, these processes can become dysregulated, leading to significant clinical implications. Thrombosis, the formation of blood clots within blood vessels, is a complex process involving platelet activation, clotting factor interactions, and endothelial cell responses. In the context of COVID-19, there is a growing recognition of a heightened thrombotic risk, with severe cases often presenting with microvascular thrombosis and macrovascular events like pulmonary embolism. The SARS-CoV-2 virus can directly impact endothelial cells, leading to a prothrombotic state characterized by increased clotting factors and diminished anticoagulant mechanisms. Understanding these underlying mechanisms is crucial for tailoring anticoagulation strategies in COVID-19 patients to mitigate the risk of thrombotic complications. Conversely, fibrinolysis is the physiological process responsible for breaking down and removing blood clots once they have served their purpose. In COVID-19 and other diseases associated with hypercoagulability, the delicate balance between thrombosis and fibrinolysis is disrupted. Research suggests that impaired fibrinolysis may contribute to the persistence of blood clots, exacerbating the prothrombotic state. Exploring the mechanisms of fibrinolysis in the context of COVID-19 is vital for identifying potential therapeutic targets aimed at restoring the equilibrium between clot formation and dissolution.[37-41]

Endothelial Dysfunction

Endothelial dysfunction, a complex and multifaceted impairment of the endothelial cells lining blood vessels, has emerged as a critical factor in the pathogenesis of various diseases, including cardiovascular disorders and infectious conditions like COVID-19. The endothelium, a dynamic monolayer of cells lining blood vessels, plays a pivotal role in regulating vascular homeostasis. Endothelial dysfunction arises when these cells lose their ability to maintain a delicate balance

between vasodilation and vasoconstriction, anticoagulation and procoagulation, and anti-inflammatory and pro-inflammatory states. In COVID-19, the SARS-CoV-2 virus has been shown to directly infect endothelial cells, triggering a cascade of events that contribute to endothelial dysfunction. This involvement is not only associated with the respiratory manifestations of the disease but also with the systemic vascular complications observed in severe cases. The consequences of endothelial dysfunction extend beyond impaired vascular tone and permeability; it significantly contributes to the hypercoagulable state observed in COVID-19. The virus-induced endothelial injury disrupts the delicate balance between prothrombotic and antithrombotic factors, culminating in a predisposition to thrombotic events. Additionally, the dysfunctional endothelium releases inflammatory mediators that further exacerbate the inflammatory response, creating a feedback loop that fuels disease progression.[42-43]

Diagnostic tools for endothelial dysfunction encompass a range of assessments, including endothelial-dependent vasodilation studies, biomarker measurements, and imaging techniques. Recognizing early markers of endothelial dysfunction becomes crucial not only for identifying individuals at risk but also for tailoring interventions to mitigate further vascular damage. The integration of endothelial health assessments into the diagnostic and prognostic arsenal for COVID-19 represents a promising avenue for improving patient management.[44] Therapeutically, interventions targeting endothelial dysfunction in COVID-19 are gaining attention. Anticoagulation strategies, anti-inflammatory agents, and medications that promote endothelial repair are among the potential approaches under investigation. Understanding the molecular and cellular mechanisms driving endothelial dysfunction allows for the development of targeted therapies aimed at restoring vascular homeostasis and ameliorating the complications associated with COVID-19.

Inflammatory Response

The inflammatory response, a fundamental component of the immune system, is a complex and highly orchestrated cascade of events designed to protect the body from harmful stimuli, including pathogens, tissue injury, and toxins. In the context of infectious diseases such as COVID-19, understanding the nuances of the inflammatory response is crucial for deciphering the pathophysiology and informing therapeutic interventions. In response to infection or injury, immune cells release signaling molecules, including cytokines and chemokines, triggering a series of events collectively known as inflammation. In COVID-19, the inflammatory response plays a dual role.[45] Initially, it serves as a vital defense mechanism to eliminate the virus and infected cells. However, in some cases, an exaggerated or dysregulated inflammatory response can lead to a phenomenon known as a cytokine storm, contributing to the severity of the disease. The immune cells involved in the inflammatory response, such as macrophages and T cells, are key players in the defense against viral infections. In COVID-19, the SARS-CoV-2 virus triggers an inflammatory cascade by interacting with host cells, particularly respiratory epithelial cells and immune cells. This interaction prompts the release of pro-inflammatory cytokines, initiating an

immune response aimed at containing and eliminating the virus. However, an overactive or prolonged inflammatory response can lead to tissue damage and contribute to the development of severe respiratory complications.

Cytokine storm, characterized by an uncontrolled release of pro-inflammatory cytokines, is a critical aspect of severe COVID-19 cases.[46] This hyperinflammatory state can lead to widespread tissue damage, particularly in the lungs, and is associated with adverse clinical outcomes. Therapeutically, managing the inflammatory response in COVID-19 has become a focal point of research. Anti-inflammatory agents, immunomodulators, and cytokine-targeted therapies are being investigated to temper the excessive immune response and prevent or mitigate the cytokine storm. Understanding the temporal dynamics of the inflammatory response is essential for tailoring interventions at different stages of COVID-19. Early modulation of the immune response may be crucial to preventing viral replication and limiting disease severity, while later interventions may focus on mitigating the hyperinflammatory state and associated complications.

Conclusion

The intricate interplay between COVID-19 and various physiological processes, including coagulation, endothelial function, and the inflammatory response, reveals the complex nature of this viral infection. Thrombosis, fibrinolysis, and endothelial dysfunction collectively contribute to the hypercoagulable state observed in severe cases, shedding light on the multifaceted impact of SARS-CoV-2 on the vascular system. Additionally, the inflammatory response, initially a vital defense mechanism, can become a double-edged sword, leading to the detrimental cytokine storm seen in severe COVID-19 cases.

References

1. Kowalik MM, Trzonkowski P, Łasińska-Kowara M, Mital A, Smiatacz T, Jaguszewski M. COVID-19—Toward a comprehensive understanding of the disease. Cardiology journal. 2020;27(2):99-114.
2. Kumar A, Narayan RK, Prasoon P, Kaur G, Kumar S, Pareek V, Faiq MA, Singh HN, Shekhawat PS, Raza K, Kumar S. COVID-19 mechanisms in the human body—What we know so far. Frontiers in immunology. 2021; 12:693938.
3. Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10(16):7448.
4. McFadyen JD, Stevens H, Peter K. The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications. Circulation research. 2020;127(4):571-587.
5. Bhat S, Rishi P, Chadha VD. Understanding the epigenetic mechanisms in SARS CoV-2 infection and potential therapeutic approaches. Virus Research. 2022; 318:198853.

Citation: Obeagu EI, Obeagu GU. Unraveling the Puzzle: COVID-19's Influence on Hemostasis Mechanisms. *Elite Journal of Haematology, 2024; 2(3):* 1-9

6. Ogar CO, Okoroiwu HU, Obeagu EI, Etura JE, Abunimye DA. Assessment of blood supply and usage pre-and during COVID-19 pandemic: a lesson from non-voluntary donation. Transfusion Clinique et Biologique. 2021;28(1):68-72.
7. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487. links/617acdd03c987366c3f8b3f1/Covid-19-and-Sickle-Cell-Anemia-Susceptibility-and-Severity.pdf.
8. Obeagu EI. COVID 19: Factors Associated with Implementation and Practice of Covid-19 Prevention. Int. J. Adv. Multidiscip. Res. 2022;9(9): 37-42.DOI: 10.22192/ijamr.2022.09.09.004
9. Nnodim J, Njoku-Obi T, Ohalete C, Obeagu EI. Perspective of Covid 19 Hesistancy. Madonna University journal of Medicine and Health Sciences. 2022;2(1):235-8.
10. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/50.
11. Obeagu EI, Babar Q, Vincent CC, Anyanwu CO. INFANTS IMMUNIZATION: CHALLENGES OF OTHER VACCINES DUE TO COVID-19 PANDEMIC. Journal of Bioinnovation. 2021;10(4):1056-66. links/6105aef21e95fe241a9e607a/INFANTS-IMMUNIZATION-CHALLENGES-OF-OTHER-VACCINES-DUE-TO-COVID-19-PANDEMIC.pdf.
12. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Chukwueze CM. A Systematic Review on the role of untreated inflammation of the genital tract in SARS COV 2 transmission. Madonna University journal of Medicine and Health Sciences. 2023;3(1):19-24. https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/98.
13. Obeagu EI, Hamisi S, Bunu UO. An update on cytokine storm in covid-19 infection: Pivotal to the survival of the patients. Int. J. Adv. Res. Biol. Sci. 2023;10(3): 171-80.DOI: 10.22192/ijarbs.2023.10.03.020
14. Obeagu EI. Mental Health Care during the COVID-19 Pandemic. Journal of Public Health and Nutrition. 2020;3(5). links/6012dc1792851c2d4dfebad6/Mental-Health-Care-during-the-COVID-19-Pandemic.pdf.
15. Asogwa EI, Obeagu EI, Abonyi OS, Elom CO, Udeoji DU, Egbumike CJ, Agunwah EU, Eze CN, Akamike IC, Esimai BN. Mitigating the Psychological Impacts of COVID-19 in Southern Nigeria; Public Awareness of Routine Exercises and Preventive Measures. Journal of Pharmaceutical Research International. 2021;33(30A):72-83.
16. Obeagu EI, Babar Q, Vincent CC, Okafor CJ, Eze R, Chijioke UO, Ibekwe AM, Uduchi IO. Pulmonary Embolism in Covid-19 Pandemic: A Threat to Recovery of the Infected Patients. Journal of Pharmaceutical Research International. 2021;33(42A):90-98.
17. Obeagu EI, Babar Q, Uduchi IO, Ibekwe AM, Chijioke UO, Okafor CJ, Vincent CC. An Update on Transfusion Related Immunomodulation (TRIM) in a Time of COVID-19 Pandemic. Journal of Pharmaceutical Research International. 2021;33(42A):135-46.
18. Okorie N, Adeniran OC, Adimabua OP, Obeagu EI, Anastasia E. Pathological Changes among Norvegicus Rattus Exposed on Novel Smoked Bambusa Vulgaris (Bamboo) Leaf:

Cigarette Substitute during COVID-19 Lockdown in Nigeria. Journal of Advances in Medical and Pharmaceutical Sciences. 2022;24(7):30-39.
19. Nakyeyune S, Ikpenwa JN, Madekwe CC, Madekwe CC, Tolulope AA, Ajayi DT, Obeagu EI, Hassan AO. COVID 19 Omicron: The Origin, Presentation, Diagnosis, Prevention and Control. Asian Journal of Research in Infectious Diseases. 2022:25-33.
20. Etido A, Obeagu EI, Okafor CJ, Chijioke UO, Vincent CC, Mojo-Eyes GC. The Dynamics of Innate and Adaptive Immune Response to Sars Cov-2 Infection and Its Limitations in Human Beings. Journal of Pharmaceutical Research International. 2021;33(45A):10-25.
21. Obeagu EI, Obeagu GU, Chukwueze CM, Ngwoke AO. Inappropriate use of personal protective equipment among health workers: A review of associated factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 27-34.DOI: 10.22192/ijcrcps.2023.10.08.004
22. Obeagu EI, Nwosu DC, Obeagu GU. Interleukin-6 (IL-6): A Major target for quick recovery of COVID-19 patients. **Int. J. Curr. Res. Biol. Med. (2022). 7(2): 1-19. DOI:** 10.22192/ijcrbm.2022.07.02.001
23. Ifeanyi OE, Mercy OH, Prayer NN, Chijindu OH. Cytokines, coagulation profile and haematological changes in covid 19 patients as indicators of their health staus: A review. European Journal of Biomedical. 2020;7(7):724-9. links/5f083f4e299bf188161034aa/CYTOKINES-COAGULATION-PROFILE-AND-HAEMATOLOGICAL-CHANGES-IN-COVID-19-PATIENTS-AS-INDICATORS-OF-THEIR-HEALTH-STATUS-A-REVIEW.pdf.
24. Obeagu EI, Scott GY, Amekpor F, Ugwu OP, Alum EU. Covid-19 Infection and Diabetes: A Current Issue. International Journal of Innovative and Applied Research. 2023;11(1):25-30.
25. Hassan AO, Obeagu EI, Ajayi DT, Tolulope AA, Madekwe CC, Madekwe CC, Ikpenwa JN, Nakyeyune S. COVID 19 Omicron: The Origin, Presentation, Diagnosis. Prevention and Control. Asian Journal of Research in Infectious Diseases. 2022;11(1):25-33.
26. Ifeanyi OE. Emerging clinical & medical challenges and appropriate solutions during COVID-19 pandemic times. Med Clin Rev. 2020;6(5):108. **DOI:** 10.36648/2471-299X.6.5.108 links/6012db46299bf1b33e30a9ec/Emerging-Clinical-Medical-Challenges-and-Appropriate-Solutions-during-Covid-19-Pandemic-Times.pdf.
27. Anyiam AF, Musa Muhibi MA, Iyare G, Omosigho PO, Olaniyan MF, Arinze-Anyiam OC, Oluwafemi E, Obeagu EI. Effects of different Extracts of Phyllantus amarus on selected haematological and haemostatic parameters of Leukemic Wistar Rats. Elite Journal of Medica Science. 2024;2(1):23-43.
28. Okoroiwu IL, Obeagu EI, Anaebo QB, Walter O. Evaluation of activated partial thromboplastin time and prothrombin time in HIV and TB patients in Owerri metropolis. J Pharm Res Int. 2022; 21:29-34.
29. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(1):292-298.

Citation: Obeagu EI, Obeagu GU. Unraveling the Puzzle: COVID-19's Influence on Hemostasis Mechanisms. *Elite Journal of Haematology, 2024; 2(3):* 1-9

30. Oloro OH, Oke TO, Obeagu EI. Evaluation of coagulation profile patients with pulmonary tuberculosis and human immunodeficiency virus in Owo, Ondo state, Nigeria. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(3):110-119.
31. Ohale AC, Obeagu EI, Mark HA, Okoli CC, Ezepue CB, Ohanu CE, Okongwu UC, Nlemadim CI, Ekeigwe IB, Okeke OA. The Sub–Acute Effects of Raw Honey on Prothrombin Time, Activated Partial Thromboplastin Time and Platelet Values in Albino Wistar Rats. Journal of Advances in Medicine and Medical Research. 2020;32(17):68-73.
32. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-6.
33. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9):41-9.
34. Obeagu EI, Babar Q, Vincent CC, Okafor CJ, Eze R, Chijioke UO, Ibekwe AM, Uduchi IO. Pulmonary Embolism in Covid-19 Pandemic: A Threat to Recovery of the Infected Patients. Journal of Pharmaceutical Research International. 2021 Aug 26;33(42A):90-8.
35. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.
36. Edward Henry SI, Obeagu EI. Assessment of the Serum Iron Status of Preeclampsia Subjects in Aba, Abia State. Elite Journal of Haematology. 2024;2(1):10-18.
37. Neubauer K, Zieger B. Endothelial cells and coagulation. Cell and tissue research. 2022;387(3):391-398.
38. Periayah MH, Halim AS, Saad AZ. Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. International journal of hematology-oncology and stem cell research. 2017;11(4):319.
39. Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. Blood reviews. 2021; 46:100733.
40. Offie DC, Ibekwe AM, Agu CC, Esimai BN, Okpala PU, Obeagu EI, Ufelle SA, Ogbonna LN. Fibrinogen and C-Reactive Protein Significance in Children Infected by Plasmodium falciparum Species in Enugu, Enugu State, Nigeria. Journal of Pharmaceutical Research International. 2021 Mar 22;33(15):1-8.
41. Obeagu E, Nwosu D, Obeagu III G. Antithrombin III: A Review. Int. J. Curr. Res. Biol. Med. 2022;7(2):20-27.
42. Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacologica Sinica. 2023;44(4):695-709.
43. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal transduction and targeted therapy. 2020;5(1):293.

Citation: Obeagu EI, Obeagu GU. Unraveling the Puzzle: COVID-19's Influence on Hemostasis Mechanisms. *Elite Journal of Haematology, 2024; 2(3):* 1-9

44. Balistreri CR. Promising strategies for preserving adult endothelium health and reversing its dysfunction: from liquid biopsy to new omics technologies and noninvasive circulating biomarkers. International journal of molecular sciences. 2022;23(14):7548.
45. García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Frontiers in immunology. 2020; 11:556786.
46. Qudus MS, Tian M, Sirajuddin S, Liu S, Afaq U, Wali M, Liu J, Pan P, Luo Z, Zhang Q, Yang G. The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection. Journal of Medical Virology. 2023;95(4): e28751.

Citation: Obeagu EI, Obeagu GU. Unraveling the Puzzle: COVID-19's Influence on Hemostasis Mechanisms. *Elite Journal of Haematology, 2024; 2(3):* 1-9